Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban,
Edoxaban) in routine treatment will recorded in this register. Within this register a
characterization of patients (with regard to demography and indication) and therapy (with
regard to medication, dose and duration) will be done. On basis of defined clinical relevant
end points the long-term efficacy and safety will be evaluated.